OOIR: Observatory of International Research

Papers

(The H4-Index of Multiple Sclerosis Journal is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	117
Sars-CoV2 infection in pregnant women with multiple sclerosis	90
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	86
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No	72
Time to move past typical syndromes in the diagnosis of multiple sclerosis	62
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	60
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	52
Therapy challenges for NMOSD in a patient with HIV	51
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	47
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	43
Decentralised clinical trials in multiple sclerosis research	43
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	42
Impact of cancer on multiple sclerosis–related healthcare and disease-modifying drug use: A multinational cohort study	42
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial	42
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	42
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab	41
Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study	40
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	38
Characterizing financial toxicity among people living with neuromyelitis optica spectrum disorder	37
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088.	36
Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab	35
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	34
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	34
Double-negative neuromyelitis optica spectrum disorder	33
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	32

Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities	32
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis	31
Optic nerve assessments in MS diagnosis are worth the added implementation complexity: Yes	31
Immunosenescence in multiple sclerosis: New insights and clinical implications	31
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study	30
Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage	30
High-risk populations should be screened for MS—Commentary	30